Robots grab chunk of prostate surgery biz
Intuitive Surgical's ramping up sales of robotic surgical arms -
and so far is alone in a $600 million market.
By Aaron Smith, CNNMoney.com staff writer
March 23 2007: 12:15 PM EDT
NEW YORK (CNNMoney.com) -- In a packed lecture hall at Cornell
University, Dr. Ash Tewari recently showed a 3D video of a robotic
claw surgically removing a prostate, as medical professionals
watched stoically and reporters squirmed in their seats.
On the screen's blown-up image, the initials of the robot's maker -
Intuitive Surgical (down $0.28 to $120.38, Charts) - were clearly
etched onto the surface of the diminutive claws. Dr. Tewari, cancer
specialist and director of robotic prostate surgery at Cornell,
believes that surgery performed with Intuitive Surgical's robot
claws is safer and quicker than the human hand, resulting in less
bleeding, with less problems of incontinence and impotence during
recovery.
Video More video
CNN's Ali Velshi talks to GlaxoSmithKline CEO Jean Pierre Garnier
about its new breast cancer drug. (March 17)
Play video
Based in Sunnyside, Calif., Intuitive Surgical makes human-guided
robotic arms that help doctors perform some of the most common and
delicate procedures - the removal of a cancerous prostate gland or
uterus - but only for those hospitals with enough money and the
right manpower.
These areas of the healthcare market - estimated at $600 million
last year by Wachovia analyst Michael Matson - are rapidly growing,
fueled by an aging U.S. population. Intuitive Surgical has already
experienced a rapid uptick in the use of its three and four-armed
da Vinci robots, with a 56 percent sales surge in 2006 to $112
million. Its stock is up 12 percent year-to-date.
Robotic removal of the prostate has been a "big home run" for
Intuitive Surgical, said Tao Levy, analyst for Deutsche Bank North
America. "By the end of the year, over half of the prostates that
are going to be removed in the U.S. are going to be done
robotically."
In 2006, 35 percent of the 90,000 prostatectomies and 2 percent of
the 250,000 hysterectomies in the U.S. were performed by Intuitive
Surgical's robots, according to Charles Olsziewski, analyst for
Oppenheimer.
The prostate gland is a small organ just below the bladder that
makes fluid for semen. Hysterectomy is removal of the uterus, the
major female reproductive organ in humans.
Medical companies take 'Fantastic Voyage' into heart
"The number of [robotic] procedures started to increase as the side
effects were taken away," said Olsziewski. He said the market
penetration for robotic prostatectomies has tripled since 2004,
primarily because robotic surgery causes less complications from
bleeding, incontinence and impotence compared to other
procedures.
Intuitive Surgical has a monopoly on robotic surgical arms.
Even if Japanese companies like Hitachi (down $0.90 to $74.36,
Charts) make good on their promises to produce robotic arms for
surgery, their potential products are years away, analysts say. So
that leaves the robotic field to Intuitive Surgical in this part of
the surgery market, where it still competes against hospitals and
physicians conducting traditional open surgeries by hand, and the
lesser-used laparoscopies, with tools provided by Johnson &
Johnson (down $0.43 to $60.43, Charts), Olympus Corp. and Tyco
(Charts).
Despite the benefits of robotic surgery, stealing market share away
from these other procedures isn't going to be easy. Not every
hospital is willing to pay $1.5 million for the newest da Vinci
robot, or to recruit, train and keep the proper specialists to run
the device.
"The chief obstacle is the commitment that the hospital has to make
to robotic procedures," said Timothy Nelson of Piper Jaffray,
noting that influential doctors need to pull together a team of
talented surgeons and technicians. "The successful programs are the
ones that get a team together. If the commitment isn't there, it
doesn't work."
But analysts believe that hospitals will have to take on the new
technology eventually to remain competitive.
"[The da Vinci] is expensive, but at the end of the day it's
allowing the hospital to do better surgery," said Levy of Deutsche
Bank North America. "Also,
hospitals without the device run the
risk of losing business to those who have it."
Sehr interessant ist bei dem artikel der letzte satz